ALDX
ALDX clinical trials: Aldeyra Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Aldeyra Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 35
- Trials linked
- 35
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ALDX on the catalyst calendar · ALDX registry changes
- Primary completion Dec 2029Sponsor estimatePhase 3NCT07402876A Clinical Trial Evaluating Patients With Primary Vitreoretinal LymphomaAldeyra Therapeutics, Inc. · Primary Vitreoretinal LymphomaRecruitingALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 21, 2023ActualPhase 2NCT05717920A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)Aldeyra Therapeutics, Inc. · Atopic DermatitisCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 18, 2025ActualPhase 2NCT06685692A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)Aldeyra Therapeutics, Inc. · Alcohol HepatitisCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 22, 2023ActualPhase 3NCT05234554The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic ConjunctivitisAldeyra Therapeutics, Inc. · Allergic ConjunctivitisCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 23, 2023ActualPhase 2NCT05392179A Study in Subjects With Retinitis PigmentosaAldeyra Therapeutics, Inc. · Retinitis PigmentosaCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 27, 2025ActualPhase 3NCT06493604A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseAldeyra Therapeutics, Inc. · Dry Eye DiseaseCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 11, 2022ActualPhase 3NCT04735393A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap...Aldeyra Therapeutics, Inc. · Dry Eye DiseaseCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 3, 2024ActualPhase 3NCT06424444A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseAldeyra Therapeutics, Inc. · Dry Eye DiseaseCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 14, 2022ActualPhase 3NCT04136366The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative VitreoretinopathyAldeyra Therapeutics, Inc. · Proliferative VitreoretinopathyCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 11, 2024ActualPhase 3NCT06389214A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye DiseaseAldeyra Therapeutics, Inc. · Dry Eye DiseaseCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2019ActualPhase 1/Phase 2NCT03660878A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic ConjunctivitisAldeyra Therapeutics, Inc. · Allergic ConjunctivitisCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 12, 2021ActualPhase 2/Phase 3NCT04674358The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseAldeyra Therapeutics, Inc. · Dry EyeCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2022ActualPhase 3NCT05062330The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseAldeyra Therapeutics, Inc. · Dry EyeCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2022ActualPhase 1/Phase 2NCT05487404A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol LevelsAldeyra Therapeutics, Inc. · Ethanol IntoxicationCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 13, 2023ActualPhase 2NCT05392192A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic CoughAldeyra Therapeutics, Inc. · Chronic CoughCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 25, 2021ActualPhase 2NCT05102409An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease ChamberAldeyra Therapeutics, Inc. · Dry EyeCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2022ActualPhase 2NCT04908514A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque PsoriasisAldeyra Therapeutics, Inc. · Plaque PsoriasisCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 8, 2021ActualPhase 2NCT04971031A Clinical Trial to Assess Subjects With Dry Eye Disease.Aldeyra Therapeutics, Inc. · Dry EyeCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2019ActualPhase 2NCT03916042A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and...Aldeyra Therapeutics, Inc. · Dry EyeCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 20, 2019ActualPhase 1/Phase 2NCT03709121A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental...Aldeyra Therapeutics, Inc. · Conjunctivitis, AllergicCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 18, 2022ActualPhase 2NCT04728711A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild...Aldeyra Therapeutics, Inc. · Atopic AsthmaCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2021ActualPhase 2NCT04847544A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for...Aldeyra Therapeutics, Inc. · Covid19CompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 5, 2018ActualPhase 3NCT03494504ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic ConjunctivitisAldeyra Therapeutics, Inc. · Allergic ConjunctivitisCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 4, 2019ActualPhase 3NCT03879863The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to...Aldeyra Therapeutics, Inc. · Dry EyeCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 19, 2019ActualPhase 3NCT03131154SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.Aldeyra Therapeutics, Inc. · Non-infectious Anterior UveitisCompletedALDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 10 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner